成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 1001600-56-1 Chemical Structure| 1001600-56-1

Structure of BV6
CAS No.: 1001600-56-1

Chemical Structure| 1001600-56-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 1001600-56-1

,{[proInfo.pro_purity]}

BV6 acts as an antagonist targeting cIAP1 and XIAP, which are members of the inhibitors of apoptosis (IAP) family.

Synonyms: BV-6 free

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BV6

CAS No. :1001600-56-1
Formula : C70H96N10O8
M.W : 1205.57
SMILES Code : O=C(NCCCCCCNC([C@@H](NC([C@H](CCC1)N1C([C@H](C2CCCCC2)NC([C@H](C)NC)=O)=O)=O)C(C3=CC=CC=C3)C4=CC=CC=C4)=O)[C@@H](NC([C@H](CCC5)N5C([C@H](C6CCCCC6)NC([C@H](C)NC)=O)=O)=O)C(C7=CC=CC=C7)C8=CC=CC=C8
Synonyms :
BV-6 free
MDL No. :MFCD28168021

Safety of BV6

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HT29 cells 2 μM 1, 2, 4 hours Induction of necroptosis in HT29 cells, stimulating RIP1 ubiquitination within the necrosome PMC5260504
GBM9 cells 0.6 μM 10 days BV6 stimulates morphological changes in GBM9 cells and increases GFAP expression, indicating that BV6 induces astrocytic differentiation of GBM9 cells. PMC3978303
A172 glioblastoma cells 2 μM 120 hours BV6 enhances TMZ-induced apoptosis, and upregulation of IFNβ is a critical event in BV6/TMZ-induced apoptosis. PMC4650438
T98G glioblastoma cells 4 μM 120 hours BV6 enhances TMZ-induced apoptosis, and upregulation of IFNβ is a critical event in BV6/TMZ-induced apoptosis. PMC4650438
L929 cells 1 μM 2 hours BV6 treatment greatly sensitized L929 cells to TNF-induced necrosis, but not to necrotic death induced by anti-Fas, poly(I:C), or oxidative stress. PMC3131911
acute lymphoblastic leukemia cells 300 nM 24 hours induces necroptotic cell death PMC5260489
mouse embryonic fibroblasts 5 μM 24 hours protects cells from BV6/Dexa-induced cell death PMC5260489
HCC193 1 μM 24 hours BV6 significantly enhanced the radiosensitivity of HCC193 cells, DER=1.38 (p<0.05). PMC3196825
FADD-deficient Jurkat T cells 1 μM 24 hours BV6 treatment sensitized FADD-deficient Jurkat T cells to TNF-induced necrosis. PMC3131911
T98G cells 2.5 μM 24 hours BV6 at non-toxic concentrations triggers cell elongation, migration, and invasion, and causes profound depletion of cIAP1 protein. PMC3615728
U87MG cells 2.5 μM 24 hours BV6 at non-toxic concentrations triggers cell migration and invasion, and causes degradation of cIAP1 and XIAP proteins. PMC3615728
LN229 cells 2.5 μM 24 hours BV6 at non-toxic concentrations triggers cell migration and invasion, and causes degradation of cIAP1 and XIAP proteins. PMC3615728
GBM1 cells 1 μM 24 hours BV6 at non-toxic concentrations triggers cell elongation, migration, and invasion, and causes profound depletion of cIAP1 protein. PMC3615728
GBM2 cells 0.8 μM 24 hours BV6 at non-toxic concentrations triggers cell elongation, migration, and invasion, and causes profound depletion of cIAP1 protein. PMC3615728
AsPc-1 5 μM 48 h To investigate whether BV6 combined with 2′3′-cGAMP can induce necroptosis in apoptosis-deficient pancreatic cancer cells, the results showed that BV6 combined with 2′3′-cGAMP significantly increased cell death, and this death could be reduced by Nec-1s inhibition of RIPK1, indicating RIPK1-dependent necroptotic cell death. PMC8405653
BxPc-3 5 μM 48 h To investigate whether BV6 combined with 2′3′-cGAMP can induce necroptosis in apoptosis-deficient pancreatic cancer cells, the results showed that BV6 combined with 2′3′-cGAMP significantly increased cell death, and this death could be reduced by Nec-1s inhibition of RIPK1, indicating RIPK1-dependent necroptotic cell death. PMC8405653
Capan-1 5 μM 48 h To investigate whether BV6 combined with 2′3′-cGAMP can induce necroptosis in apoptosis-deficient pancreatic cancer cells, the results showed that BV6 combined with 2′3′-cGAMP significantly increased cell death, and this death could be reduced by Nec-1s inhibition of RIPK1, indicating RIPK1-dependent necroptotic cell death. PMC8405653
DanG 5 μM 48 h To investigate whether BV6 combined with 2′3′-cGAMP can induce necroptosis in apoptosis-deficient pancreatic cancer cells, the results showed that BV6 combined with 2′3′-cGAMP significantly increased cell death, and this death could be reduced by Nec-1s inhibition of RIPK1, indicating RIPK1-dependent necroptotic cell death. PMC8405653
H460 5 μM 48 hours BV6 significantly enhanced the radiosensitivity of H460 cells, DER=1.42 (p<0.05). PMC3196825
UoCB6 66.1 nM 48 hours BV6 induced cell death, primarily through TNF-α-dependent apoptosis PMC4816168
REH 251.1 nM 48 hours BV6 induced cell death, primarily through TNF-α-dependent apoptosis PMC4816168
GBM10 cells 1 μM 7 days BV6 stimulates morphological changes in GBM10 cells and increases GFAP expression, indicating that BV6 induces astrocytic differentiation of GBM10 cells. PMC3978303
Non-malignant neural stem cells (NSCs) 1 μM 7 days BV6 does not alter cell morphology, differentiation, or expression of stemness markers in NSCs. PMC3978303
A172 glioblastoma cells 5 μM 72 hours To investigate the mechanism of BV6-induced apoptosis, it was found that BV6 upregulates DR5 expression in an NF-κB-dependent manner, thereby promoting apoptosis. PMC3847333
MDA-MB-231 breast carcinoma cells 50 nM 72 hours To investigate the mechanism of BV6-induced apoptosis, it was found that BV6 induces apoptosis through the TNFα/TNFR1 autocrine/paracrine signaling pathway. PMC3847333
MDA-MB-231 cells 50 nM 72 hours To evaluate BV6-induced cell death, results showed that IRF1 knockdown significantly reduced BV6-induced cell death. PMC4454156
T24 cells 100 nM 72 hours To evaluate BV6-induced cell death, results showed that IRF1 knockdown significantly reduced BV6-induced cell death. PMC4454156
SK-N-AS cells 50 nM 72 hours To evaluate BV6-induced cell death, results showed that IRF1 knockdown significantly reduced BV6-induced cell death. PMC4454156
Kym1 cells 100 nM 72 hours To evaluate BV6-induced cell death, results showed that IRF1 knockdown significantly reduced BV6-induced cell death. PMC4454156
H1299 cells 1 μM various time periods To evaluate the effect of BV6 on cIAP1 and cIAP2 protein levels, results showed that cIAP2 degradation was protected in H1299 cells PMC4532773

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
WT and Ccr2?/? mice acute sclerosing cholangitis model intrabiliary injection single intrabiliary injection single injection, continued for 5 days inhibition of monocyte/macrophage recruitment by genetic or pharmacological depletion of CCR2 reduces biliary injury and fibrosis PMC6098983
Athymic Nude mice Orthotopic and subcutaneous GBM models Injection 0.6 mM Single injection, observed until clinical symptoms appeared BV6 treatment reduces clonogenicity and tumorigenicity of GBM CSLCs in vivo and significantly increases the survival of mice. PMC3978303
Nude mice xenograft tumor model intraperitoneal injection 10 mg/kg every 4 days, total four treatments To evaluate the tumor suppressive effect of BV6, results showed that USP11 downregulation enhanced the antitumor activity of BV6 and TRAIL PMC4532773
NOD/SCID mice huALL model intraperitoneal injections 10 mg/kg twice per week for 2 weeks BV6 significantly reduced leukemia load and prolonged leukemia-free survival, and this effect was dependent on TNF-α PMC4816168
Chicken embryos Chicken chorioallantoic membrane model Implantation on the chicken chorioallantoic membrane 2.5 μM Single administration, lasting 4 days Pre-treatment with BV6 significantly increased the infiltrative growth of GBM cells, indicating that BV6 enhances the invasiveness of GBM cells in vivo. PMC3615728

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.83mL

0.17mL

0.08mL

4.15mL

0.83mL

0.41mL

8.29mL

1.66mL

0.83mL
Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories